GUJTHEM
Gujarat Themis Biosyn Limited (GUJTHEM) Stock Analysis
Gujarat Themis Biosyn Limited is an Indian pharmaceutical company producing fermentation-based APIs and biosimilars. It manufactures antibiotics and statin intermediates for global pharma customers. The company operates biotech manufacturing in Gujarat. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹397.60
-3.90% 1W | +2.90% 52W
Market Cap
5.2k CR
P/E Ratio
89.1
52W High
₹479
52W Low
₹225.1
Div. Yield
0.16%
Beta
0.5
50 DMA
₹389.6
200 DMA
₹360
Profit Margin
28%
Inst. Own.
3.2%
📉 CONSOLIDATING DOWN
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 36 | 44 | 44 |
| Expenses | 22 | 25 | 23 |
| Operating Profit | 14 | 19 | 21 |
| OPM % | 39% | 44% | 48% |
| Other Income | 0 | 1 | 0 |
| Interest | 0 | 2 | 2 |
| Depreciation | 2 | 4 | 4 |
| Profit before tax | 12 | 14 | 15 |
| Tax % | 25% | 24% | 27% |
| Net Profit | 9 | 11 | 11 |
| EPS in Rs | 0.83 | 1.00 | 1.02 |
| Metric | Mar 2026 |
|---|---|
| Sales | 166 |
| Expenses | 90 |
| Operating Profit | 76 |
| OPM % | 46% |
| Other Income | 2 |
| Interest | 3 |
| Depreciation | 13 |
| Profit before tax | 62 |
| Tax % | 25% |
| Net Profit | 47 |
| EPS in Rs | 4.28 |
| Dividend Payout % | 0% |
Shareholding Pattern
Promoters70.87%
FIIs2.95%
DIIs1.17%
Public25.01%
Promoters70.87%
FIIs1.96%
DIIs1.17%
Public26.00%
Promoters70.86%
FIIs1.80%
DIIs1.17%
Public26.15%
Promoters70.87%
FIIs1.76%
DIIs1.17%
Public26.18%
Promoters59.33%
FIIs4.93%
DIIs13.79%
Public21.95%
Promoters75.00%
FIIs0.01%
DIIs0.03%
Public24.95%
Promoters70.87%
FIIs1.05%
DIIs0.82%
Public27.26%
Promoters70.87%
FIIs1.91%
DIIs1.17%
Public26.05%
Promoters70.86%
FIIs1.80%
DIIs1.17%
Public26.15%
Promoters59.33%
FIIs4.93%
DIIs13.79%
Public21.95%
GUJTHEM
Holdings Analysis
Key strengths & risk signals
62
Overall
52
Fundamental
73
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
POSITIVE YEAR! Stock gained 2.9% in the last year.
WEAK MOMENTUM! Limited price growth - -3.9% (1 week), -3.3% (1 month), 0.0% (3 months).
Strengths (4)
EXCELLENT EFFICIENCY! 28.0% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (389.6) is above 200-day average (360.0) - positive signal.
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 654,848 vs down days: 514,462. Ratio: 1.27x
Fundamental & Technical Analysis
62Overall
52Fundamental
73Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.8% (SLOW, 5/15). Profit CAGR: -7.0% (DECLINING, 2/15).
Profit Margin
9/10
EXCELLENT EFFICIENCY! 28.0% profit margin - company keeps strong profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.16% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.95% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (389.6) is above 200-day average (360.0) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (397.6) is above both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
4/10
POSITIVE YEAR! Stock gained 2.9% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 654,848 vs down days: 514,462. Ratio: 1.27x
RSI
3/5
NEUTRAL! RSI at 45.6 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 67.9% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -3.9% (1 week), -3.3% (1 month), 0.0% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
GUJTHEM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-14 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GUJTHEM | ₹397.60 | 89.1 | 28.0% | 3.8% | -7.0% | +2.9% | 62 | APPROACHING RESISTANCE | +22.0% | +1.8% | +22.0% | -0.9% |
| ORCHPHARMA | ₹1,023.40 | 320.8 | 3.5% | 22.3% | -40.1% | +49.9% | 71 | CONSOLIDATING DOWN | -156.1% | -86.6% | +15.6% | +28.0% |
| FDC | ₹343.60 | 19.1 | 13.4% | 6.8% | 13.2% | -23.9% | 68 | BREAKOUT | +9.1% | +28.1% | +3.0% | +14.2% |
| IOLCP | ₹196.30 | 34.3 | 6.7% | 1.6% | -0.4% | +101.6% | 60 | BREAKDOWN | +90.0% | +21.1% | +37.1% | +22.1% |
| SPARC | ₹202.80 | 4.2 | 83.0% | -45.3% | – | +62.3% | 65 | BREAKOUT | -59.9% | -101.2% | +315.6% | -97.8% |
| MOREPENLAB | ₹120.70 | 47.2 | 7.2% | 8.4% | 34.9% | +150.4% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| INNOVACAP | ₹1,271.20 | 47.3 | 8.8% | 20.1% | 27.5% | +54.6% | 74 | APPROACHING SUPPORT | +42.3% | +15.7% | +34.0% | +5.2% |
| BLISSGVS | ₹737.60 | 58.5 | 13.5% | 7.2% | 22.1% | +378.2% | 73 | CONSOLIDATING DOWN | +16.5% | +40.7% | +37.6% | +11.1% |
Data from TradeAlone · Updated daily
GUJTHEM News
Gujarat Themis Biosyn Limited (gujthem) Q1 FY27: Topline Surges 22%, PAT Improves 22%2026-08-07Gujarat Themis Biosyn Limited Announces Strategic Acquisitions and Expansion Plans2026-06-29Gujarat Themis Biosyn Limited (gujthem) Q4 FY26: Strong Revenue Growth, Margin Expansion, and Strategic Acquisitions2026-05-25
